Skip to content
mesothelioma chemotherapy

Implantable chemotherapy treatments

Designed to deliver the chemotherapy medication called carmustine, the Gliadel® wafer can be placed and left inside the cavity created after a brain tumor (especially glioblastoma multiforme) is surgically removed. This special carmustine wafer formulation allows doctors to administer the drugs exactly at the site of occurrence of the brain tumor. After removing the cancerous tissues from the brain, the surgeon places up to 8 wafers (dime-sized) inside the surgical cavity, the space that was earlier occupied by the tumor. The wafers continue to dissolve over the next two to three weeks, delivering the chemo medication to the surrounding cells. The objective of this treatment procedure is to destroy cancer cells that may remain after surgery.

Topical chemotherapy treatments

To treat certain types of skin cancer, some chemotherapy creams are administered directly to the skin surface. Absorbed via the skin, the cream eventually reaches the cancerous lesion. However, use of topical medications for the treatment of cancer is fairly limited.

 

This website is sponsored by Brad Cooper* of The Cooper, Hart, Leggiero, & Whitehead, PLLC. Cooper, Hart, Leggiero, & Whitehead is located in The Woodlands, Texas (Greater Houston Area) and can be reached toll free at 1-800-998-9729 for more information on mesothelioma. Brad Cooper is not a medical doctor. The information on these pages is for the education of mesothelioma patients and their families regarding potential medical and legal options. Patients are advised to consult with a medical doctor.

*  Licensed by the Supreme Court  of Texas.

 

 

 

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a clinical practice guideline.

Advances in the systemic therapy of malignant pleural mesothelioma

Kinase Inhibitors for Mesothelioma Treatment

journal abstracts

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

The second wave in kinase cancer drugs

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma


Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.